Advanced Enzyme Technologies Limited (ADVENZYMES) share price
₹293.40 on NSE as of 2026-09-11. -3.28% on the day. market cap ₹3,278 Cr. P/E 19.8. 52-week range ₹255.30 to ₹392.10. Healthcare.
Advanced Enzyme Technologies Q1 FY27: Revenue ₹189.79 Cr, a ₹10 Cr Sale Stuck in Transit, and a ₹69.7 Cr Buyback
At a glance
Advanced Enzyme Technologies closed the June 2026 quarter with revenue of ₹189.79 crore, operating profit of ₹50.97 crore and net profit of ₹37.09 crore. Management described the quarter as a "softer, more muted start."
Inside that sentence sits one of the more literal explanations available in Indian corporate reporting: roughly ₹10 crore of sales spent the quarter in transit. Management said it relates to "sale in the transit, which is not reached to the customer," and therefore could not be recognised until "risk and reward is transferred to the customer." Somewhere on a container ship, revenue was floating.
The board meeting of August 8, 2026 was busier than the quarter. It approved the results, a buyback of up to ₹697 million at a maximum ₹500 per share, the purchase of the last 4.28% of JC Biotech for ₹79.79 million, and an infusion of up to ₹20 million into Advanced Nutrazyme. That is four decisions in seventy-five minutes — the meeting commenced at 10.00 a.m. and concluded at 11.15 a.m., which for a board approving a buyback is brisk.
Operating margin came in at 27% for the quarter, against 30% in Q1 FY26 and 31% in Q4 FY26. Management attributed the compression to "lower top-line realization," "elevated power and fuel costs driven by global energy disruption," and a "temporary shift in the sales mix."
Full-year FY26 revenue was ₹745.76 crore with net profit of ₹168.72 crore. The company sells enzymes — proteins that make chemical reactions hurry up. The financial year, by contrast, took its time.
Introduction
The company was incorporated in 1989 as Advanced Biochemicals Pvt Ltd by Mr V L Rathi and Mr C L Rathi, per Crisil's rating rationale, and renamed Advanced Enzyme Technologies Limited in 2005. Its first fermentation facility was commissioned at Sinnar, Maharashtra in 1994. By 2001 Advanced Biochemicals was ranked the largest domestic manufacturer of industrial enzymes, and it filed its first patent in 2004 — a fifteen-year run of quietly growing microorganisms before anyone thought to write it down.
Listing came in August 2016 on both exchanges, alongside the acquisition of a 70% stake in JC Biotech with its fermentation facility at Ongole, Andhra Pradesh. The decade since reads as a list of stake increases in the same subsidiary: 70% in 2016, up 15% in 2018, up 5.89% in February 2024 to 95.72%, and now the final 4.28% for ₹79.79 million at ₹90 per share. Ten years to buy one company, in five separate visits. JCB's turnover was ₹728 million in FY26, ₹600 million in FY25 and ₹627 million in FY24.
Other acquisitions arrived along the way: Cal India Foods International in 2011 for a US presence, evoxx technologies GmbH in Germany in 2017, 51% of SciTech Specialities in 2021, 50% of SaiGanesh Enzytech in 2024. In 2025 the company established Starya Labs for independent testing of enzymes and probiotics, incorporated Advanced Nutrazyme Private Limited on July 4 for nutrition and wellness distribution, and commissioned a 510kW solar power plant.
The consolidated results for the June 2026 quarter include the holding company and thirteen subsidiaries across India, the USA, the Netherlands and Germany. The auditors, M S K A & Associates LLP, expressed an unmodified conclusion, noting they did not review four subsidiaries themselves and relied on other auditors' reports, and that another four subsidiaries — total revenue ₹77.16 million — were not reviewed by any auditor at all, being management-certified and, per the report, "not material to the Group."
The board also saw a change in June 2026: Ms Rajshree Patel served as Independent Director up to June 11, 2026, and Mr Pradip Shah joined as Independent Director effective June 12, 2026. A one-day handover, which is either excellent planning or an excellent calendar.
Business model
Enzymes are, in the company's own description, natural protein molecules that act as catalysts within living cells, produced by all living organisms. Advanced Enzymes uses them to replace chemicals in industrial processes. Probiotics — live microorganisms administered in sufficient amount — are the other half of the shelf.
The physical operation: 9 manufacturing units (8 in India, 1 in the USA), 7 R&D units (5 India, 1 USA, 1 Germany), 500 cubic metres of fermentation capacity, and 30+ years of fermentation experience. Five hundred cubic metres is roughly a fifth of an Olympic pool, permanently full of things multiplying. The portfolio runs to 68+ enzymes and probiotics from which 400+ proprietary products are built, sold to 700+ customers across 45+ countries by 750+ employees. That is one enzyme for every eleven employees, which feels like a manageable pet-to-owner ratio.
Four segments carry the revenue. **Human Healthcare** was 60% of Q1 FY27 sales at ₹1,139 million, down 7% year-on-year — management attributed the decline primarily to "lower sales in the Pharma API business," offset partly by an observed improvement in B2C revenue in the USA. **Animal Healthcare** at 13% (₹252 million, -3% YoY) sells feed additives that help animals extract more nutrients from feed, which is to say the company sells digestion as a product to poultry and swine. **Industrial Bio-processing** at 16% (₹306 million, +30% YoY) splits into food enzymes at ₹263 million, up 51%, and non-food at ₹43 million, down 30% — the enzymes that go into baking, brewing, textiles, leather, detergent and pulp & paper. **Specialized Manufacturing** at 11% (₹200 million, +41% YoY) makes effervescent tablets and sachets, so somewhere in this enzyme empire there is a division whose entire competitive advantage is fizzing correctly.
Geographically, Q1 FY27 revenue was India ₹937 million (49%), Americas ₹546 million (29%), Asia ex-India ₹242 million (13%), Europe ₹132 million (7%) and Rest of the World ₹40 million (2%).
Management described a deliberate shift in the US toward branded ingredients — the CFO said "we are trying to brand most of our products," clarifying it remains B2B, with the logic that "Once the label is with your name, then it becomes a kind of a sticky business." On manufacturing, the CFO was firm: "from the fermentation side, we will always continue to do it in India," citing the capital required to build US capability. On US growth, management said "we don't expect at least at this juncture beyond 8–10% of growth."
The regulatory paperwork is its own product line: 17 food enzyme dossiers filed with EFSA, 10 GRAS dossiers evaluated by US FDA, 1 novel food dossier under evaluation, 15 patents. On EFSA timelines, management said "It's a long process… depends on the authorities… maybe three months to six months… [but] you never know," and noted they are "still waiting from 2014" on another filing. Twelve years is a long time to hold a form.
Quarterly results, balance sheet, cash flow, ratios, shareholding and the filings themselves are on the full page for Advanced Enzyme Technologies Limited.
Companies in the same industry as Advanced Enzyme Technologies Limited
Biotechnology